LabGenius Therapeutics will present preclinical data for LGTX-101, its AI-designed Nectin-4 x CD3 T-cell engager, at AACR 2026 in San Diego.
Morning Overview on MSN
Researchers map real-time signals that trigger T cell activation
A cluster of recent studies has sharpened the scientific picture of how T cells switch on, tracking the molecular signals ...
T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on ...
Aptevo Therapeutics Inc. has added a preclinical candidate, APVO-455, to its portfolio of CD3-directed candidates built on the CRIS-7-derived CD3 binding domain.
New findings reveal how cancer manipulates immune pathways and highlight therapeutic strategies to unleash T-cells against even the most resistant tumors. Study: Cancer cells impair monocyte-mediated ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea’s proprietary in vivo CAR T platform Peer-reviewed publication demonstrates stable, cell-specific transgene expression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results